Quarterly ResultAug 5, 2026, 04:34 PM
Innoviva H1 Net Income $103.2M; Q2 Net Loss $(83.4)M
AI Summary
Innoviva reported a mixed financial performance for the first half of 2026, with net income soaring to $103.2 million, a 503% increase year-over-year. However, the second quarter of 2026 saw a net loss of $(83.4) million, primarily due to negative fair value adjustments on equity and long-term investments. Total revenue for Q2 increased by 19.2% to $119.6 million, driven by a 45.9% rise in net product sales. The company also noted the FDA approval of NUZOLVENCE® in December 2025, with commercial availability expected in the second half of 2026, and repurchased $51.3 million in common stock during H1.
Key Highlights
- H1 2026 Net Income: $103.2 million, up 503% from $17.1 million in H1 2025.
- H1 2026 Diluted EPS: $1.25, up 410% from $0.24 in H1 2025.
- Q2 2026 Net Loss: $(83.4) million, compared to net income of $63.7 million in Q2 2025.
- Q2 2026 Total Revenue: $119.6 million, up 19.2% from $100.3 million in Q2 2025.
- Q2 2026 Net Product Sales: $51.8 million, up 45.9% from $35.5 million in Q2 2025.
- NUZOLVENCE® FDA approval on December 12, 2025, with H2 2026 availability.
- Repurchased $51.3 million of common stock in H1 2026.
Price Impact
More from INVA